全文获取类型
收费全文 | 3155019篇 |
免费 | 235237篇 |
国内免费 | 4746篇 |
专业分类
耳鼻咽喉 | 44836篇 |
儿科学 | 104990篇 |
妇产科学 | 85885篇 |
基础医学 | 459062篇 |
口腔科学 | 86772篇 |
临床医学 | 284157篇 |
内科学 | 611553篇 |
皮肤病学 | 69644篇 |
神经病学 | 249538篇 |
特种医学 | 119998篇 |
外国民族医学 | 1096篇 |
外科学 | 477548篇 |
综合类 | 67337篇 |
现状与发展 | 12篇 |
一般理论 | 1118篇 |
预防医学 | 246874篇 |
眼科学 | 74017篇 |
药学 | 235430篇 |
12篇 | |
中国医学 | 6132篇 |
肿瘤学 | 168991篇 |
出版年
2019年 | 24976篇 |
2018年 | 34777篇 |
2017年 | 26149篇 |
2016年 | 29283篇 |
2015年 | 33020篇 |
2014年 | 46525篇 |
2013年 | 70288篇 |
2012年 | 96776篇 |
2011年 | 103010篇 |
2010年 | 61455篇 |
2009年 | 58146篇 |
2008年 | 97086篇 |
2007年 | 103737篇 |
2006年 | 104662篇 |
2005年 | 101413篇 |
2004年 | 97686篇 |
2003年 | 94255篇 |
2002年 | 91746篇 |
2001年 | 144750篇 |
2000年 | 149002篇 |
1999年 | 126084篇 |
1998年 | 36525篇 |
1997年 | 32191篇 |
1996年 | 32574篇 |
1995年 | 30888篇 |
1994年 | 28719篇 |
1993年 | 26836篇 |
1992年 | 98549篇 |
1991年 | 96557篇 |
1990年 | 93997篇 |
1989年 | 90214篇 |
1988年 | 83036篇 |
1987年 | 81824篇 |
1986年 | 76470篇 |
1985年 | 73598篇 |
1984年 | 55012篇 |
1983年 | 46714篇 |
1982年 | 27729篇 |
1981年 | 24977篇 |
1979年 | 50367篇 |
1978年 | 35731篇 |
1977年 | 30012篇 |
1976年 | 28483篇 |
1975年 | 30773篇 |
1974年 | 36490篇 |
1973年 | 34925篇 |
1972年 | 32575篇 |
1971年 | 30485篇 |
1970年 | 28420篇 |
1969年 | 26749篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
941.
942.
N. N. Polygalova A. G. Mikhailovskii E. S. Limanskii B. Ya. Syropyatov M. I. Vakhrin 《Pharmaceutical Chemistry Journal》2006,40(3):132-134
A series of 1-alkyl-3,4-dihydroisoquinolines and the related 4-alkyl-1,2-dihydro-benzo[f]isoquinolines was synthesized using
reactions of dialkylbenzylcarbinols and their naphthyl analogs with alkylcyanides. Experiments showed that 1-alkyl-6,7-dimethoxy-3,4-dihydroisoquinolines
typically produce a hypotensive action, while the benzo-annelated structures usually exhibit a hypertensive effects. The most
active compound decreases the arterial pressure in cats by 52 Torr and the effect lasts for about 4 hours.
__________
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 3, pp. 15–17, March, 2006. 相似文献
943.
I. V. Shilova E. A. Krasnov E. I. Korotkova M. G. Nagaev A. N. Lukina 《Pharmaceutical Chemistry Journal》2006,40(12):660-662
Extracts of the above-ground part of meadowsweet (Filipendula ulmaria L. Maxim.) demonstrate a pronounced antioxidant activity. It is established that 70% and 95% ethanol extracts contain the
most active substances. Investigation of the chemical composition of the above-ground part of the plant and its 70% ethanol
extract by means of qualitative reactions, thin-layer chromatography, and paper chromatography showed the presence of various
phenolic compounds, including quercetin and its glycosides, dihydroquercetin, apigenin, rododendrol, esculetin, and m-hydroxybenzoic, salicylic, anisic, gallic, gentisic, ferulic, chlorogenic, and caffeic acids.
__________
Translated From Khimiko-Farmatsevticheskii Zhurnal, Vol. 40, No. 12, Pp. 22–24, December, 2006. 相似文献
944.
目的:直肠腺瘤和其他疑似为良性的病变应用经肛门内镜切除术并未普及。该项研究旨在评估经肛门内镜切除术的效能和安全性。方法:回顾性研究分析在1993-2004年之间3所斯德哥尔摩医院中经肛门内镜切除术的患,内容包括患自身及病变特性、并发症、随访时间和复发率。结果:180例中共131例行经肛门内镜切除术。160例经组织学诊断为腺瘤,12例为癌瘤,其余8例分别为增生、纤维化或正常黏膜。直肠腺瘤患中,77例仅行单次经肛门内镜切除术,16例因巨大腺瘤而多次行该手术,27例因复发而需另行经肛门内镜切除术或其他手术。中位复发时间为7个月,但未出现直肠癌。16例手术患出现并发症。2例患必须行Hartman手术,1例因肠穿孔,另1例因出血。手术期间无死亡。未复发的中位随访期为32个月(极差0—67)。[编按] 相似文献
945.
946.
Four clinical trials of porcine islet transplantation have been reported, and there are verbal reports that clinical trials on much larger scales are continuing in centers in China and Russia. The four reported trials are briefly reviewed and, in the light of the present status of experimental islet xenotransplantation, consideration is given to whether such trials are currently justified. The Ethics Committee of the International Xenotransplantation Association has (1) emphasized the need for encouraging studies in non-human primates before clinical trials should be undertaken, (2) mandatory monitoring for the transfer of porcine microorganisms, and (3) careful regulation and oversight by recognized bodies. Other aspects of the topic, such as the need for informed consent, are briefly discussed. We conclude that, at the present time, more data documenting convincing efficacy, focused on clinically applicable immunosuppressive regimens, are needed to justify the initiation of closely monitored clinical trials. A clinical trial may then be justified even though the potential risk to the patients, and possibly for society, will not be zero. 相似文献
947.
T. M. Egan S. Murray R. T. Bustami T. H. Shearon K. P. McCullough L. B. Edwards M. A. Coke E. R. Garrity S. C. Sweet D. A. Heiney F. L. Grover 《American journal of transplantation》2006,6(5P2):1212-1227
This article reviews the development of the new U.S. lung allocation system that took effect in spring 2005. In 1998, the Health Resources and Services Administration of the U.S. Department of Health and Human Services published the Organ Procurement and Transplantation Network (OPTN) Final Rule. Under the rule, which became effective in 2000, the OPTN had to demonstrate that existing allocation policies met certain conditions or change the policies to meet a range of criteria, including broader geographic sharing of organs, reducing the use of waiting time as an allocation criterion and creating equitable organ allocation systems using objective medical criteria and medical urgency to allocate donor organs for transplant. This mandate resulted in reviews of all organ allocation policies, and led to the creation of the Lung Allocation Subcommittee of the OPTN Thoracic Organ Transplantation Committee. This paper reviews the deliberations of the Subcommittee in identifying priorities for a new lung allocation system, the analyses undertaken by the OPTN and the Scientific Registry for Transplant Recipients and the evolution of a new lung allocation system that ranks candidates for lungs based on a Lung Allocation Score, incorporating waiting list and posttransplant survival probabilities. 相似文献
948.
949.
950.
B Nkgudi K A Robertson J Volmink B M Mayosi 《Suid-Afrikaanse tydskrif vir geneeskunde》2006,96(3):206-208
OBJECTIVE: To determine whether under-reporting of rheumatic fever occurs at hospital, municipal, provincial and national levels of the South African health system. BACKGROUND: Information on the incidence of rheumatic fever (RF) and the prevalence of rheumatic heart disease (RHD) is required for the prevention of valvular heart disease in developing countries. In South Africa, RF was made a notifiable condition in 1989. It has recently been suggested that the reporting of RF cases may be incomplete, possibly because of underreporting by health care professionals and deficient administration of the disease notification system in South Africa. METHOD AND RESULTS: We assessed whether underreporting of RF cases occurs by comparing the numbers of RF cases reported per year at hospital, municipal, provincial and national levels from 1990 to 2004. There was a fall in the number of RF cases reported per year at national and provincial level over the 15 years of observation. A detailed analysis of the number of RF cases reported at hospital, municipal and provincial level for a 5-year period showed that more cases were diagnosed in one hospital (serving a smaller population) than were captured at municipal and provincial level (serving a larger population), suggesting underreporting by health care professionals. There were discrepancies in the number of cases reported at municipal, provincial and national level, suggesting poor administration of the notification system. CONCLUSION: There appears to be underreporting of RF cases by health care professionals, and poor administration of the RF notification system. Health care professionals need to be educated about the statutory requirement to notify all RF cases in South Africa. An effective national disease notification system is required. 相似文献